Soleno Therapeutics Inc. (SLNO)
73.92
-0.31 (-0.42%)
At close: Apr 25, 2025, 11:08 AM
Company Description
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program.
The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017.
Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Soleno Therapeutics Inc.
| Country | United States |
| IPO Date | Nov 13, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 92 |
| CEO | James H. MacKaness |
Contact Details
Address: 203 Redwood Shores Parkway Redwood City, California United States | |
| Website | https://soleno.life |
Stock Details
| Ticker Symbol | SLNO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001484565 |
| CUSIP Number | 834203200 |
| ISIN Number | US8342033094 |
| Employer ID | 77-0523891 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| James H. MacKaness | Chief Financial Officer & Compliance Officer |
| Dr. Michael Huang M.D. | Senior Vice President of Clinical Development |
| Dr. Mitchell Nagao M.B.A., Pharm.D. | Senior Vice President of Medical Affairs |
| Patricia C. Hirano M.P.H. | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2025 | ARS | Filing |
| Apr 22, 2025 | DEFA14A | Filing |
| Apr 22, 2025 | DEF 14A | Filing |
| Apr 18, 2025 | 8-K | Current Report |
| Apr 02, 2025 | 4 | Filing |
| Mar 31, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Mar 31, 2025 | 4 | Filing |
| Mar 31, 2025 | 4 | Filing |
| Mar 31, 2025 | 4 | Filing |
| Mar 31, 2025 | 4 | Filing |